TrialClinical and translational science2023

Exposure-response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040).

Bruno Sangro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.